Go here to read the rest:
Natural Alternatives International, Inc. Announces Fiscal 2024 Q4 and YTD Results
Related Post
- Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules - September 28th, 2024
- Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed - September 28th, 2024
- Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital - September 28th, 2024
- AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment - September 28th, 2024
- ImPact Biotech Announces 50% Enrollment in Phase 3 ENLIGHTED Clinical Trial of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer - September 28th, 2024
- Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) suggest high response rates and durable responses in triple-class... - September 28th, 2024
- Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress - September 28th, 2024
- TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients... - September 28th, 2024
- Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day - September 28th, 2024
- Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission - September 28th, 2024
- Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained... - September 28th, 2024
- Burning Rock Announces Changes to Management and Board of Directors - September 28th, 2024
- Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD - September 28th, 2024
- Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray - September 28th, 2024
- Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD - September 28th, 2024
- DARZALEX® (daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly... - September 28th, 2024
- CARVYKTI® ▼ (ciltacabtagene autoleucel; cilta-cel) is the first cell therapy to significantly extend overall survival versus standard therapies for... - September 28th, 2024
- CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma... - September 28th, 2024
- BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause... - September 28th, 2024
- INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort - September 26th, 2024
- Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis - September 26th, 2024
- Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue - September 26th, 2024
- Interim results for the six months ended June 30, 2024 - September 26th, 2024
- Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with... - September 26th, 2024
- Kane Biotech Announces Attendance at Upcoming Wound Care Conferences - September 26th, 2024
- Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of... - September 26th, 2024
- Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - September 26th, 2024
- Fortress Biotech to Participate in October 2024 Investor Conferences - September 26th, 2024
- Units for Debt Settlement - September 26th, 2024
- Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously... - September 26th, 2024
- Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa - September 26th, 2024
- SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - September 26th, 2024
- GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - September 26th, 2024
- Kaida BioPharma to Present at BioSparkVA Pitch Event - September 26th, 2024
- CannaCon Midwest Convenes in Cleveland October 2024 - September 26th, 2024
- BioNTX Announces 2024 Tech Transfer Showcase Finalists Pitch Competition at the 2024 iC³ Life Science & Healthcare Innovation Summit - September 26th, 2024
- Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines - September 26th, 2024
- Bavarian Nordic Upgrades its Financial Guidance for 2024 - September 26th, 2024
- Urteste Expands Development of Innovative Diagnostic Projects - September 26th, 2024
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer - September 25th, 2024
- UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024 - September 25th, 2024
- Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - September 25th, 2024
- Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of... - September 25th, 2024
- CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - September 25th, 2024
- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials - September 25th, 2024
- Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration - September 25th, 2024
- Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe... - September 25th, 2024
- Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer... - September 25th, 2024
- Conception Nurseries Launches TrueClones™ X - September 25th, 2024
- Tersa Earth and Silica-X Sign MoU to Revolutionize Mining and Waste Management with AI-Powered Biotech and Zero-Waste Solutions - September 25th, 2024
- Georgiamune Announces First Participant Dosed in First-In-Class Phase 1 Healthy Volunteers Trial of GIM-407 - September 25th, 2024
- Appointment of Dr. Kalpesh Barot, MD Completes Phase One of ADIA Nutrition’s Medical Division - September 25th, 2024
- GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024 - September 25th, 2024
- Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for... - September 25th, 2024
- Eurobio Scientific: RESULTS FOR THE 1ST HALF OF 2024 - September 25th, 2024
- Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines - September 25th, 2024
- CARBIOS and Selenis announce strategic partnership to produce PETG issued from CARBIOS’ biorecycling technology for Cosmetic and Healthcare markets - September 25th, 2024
- Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug... - September 25th, 2024
- Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day - September 25th, 2024
- Kineta, Inc Transitioning from Nasdaq to OTC Markets - September 20th, 2024
- Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit - September 20th, 2024
- Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference - September 20th, 2024
- Financière de Tubize - Transparency notification - September 20th, 2024
- Inbiome, developing a new PCR technology capable of simultaneous identification of hundreds of bacterial pathogens in a single test, welcomes... - September 20th, 2024
- Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination - September 20th, 2024
- 213,285 Orion Corporation A shares converted into B shares - September 20th, 2024
- DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple... - September 20th, 2024
- Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive... - September 20th, 2024
- Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old - September 20th, 2024
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union - September 20th, 2024
- Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old - September 20th, 2024
- Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed - September 20th, 2024
- Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade - September 20th, 2024
- Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with... - September 20th, 2024
- Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - September 20th, 2024
- T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union - September 20th, 2024
- Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs - September 20th, 2024
- Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 - September 20th, 2024
- Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders - September 20th, 2024
- Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World... - September 18th, 2024
Recent Comments